New treatments for osteoarthritis must be based on evidencedoi:10.1016/S2665-9913(19)30133-XFiona E WattThe Lancet Rheumatology
Osteoarthritis (OA) is the most common form of arthritis and is among the top 10 conditions contributing to Years Lived with Disability—a measure reflecting the impact an illness has on quality of life before it resolves or leads to death. To date, no treatments are approved that slow diseas...
A new review by David A. Walsh and Joanne Stocks in theSeptember 2017 issue ofSLAS Discovery(formerly theJournal of Biomolecular Screening) explores evolving treatments and future therapies for osteoarthritis (OA) pain. It covers the limitations of existing treatments and introduces the latest understa...
These risk factors are particularly important in the weight-bearing joints, and modifying them may help prevent osteoarthritis-related pain and disability. Major advances in management to reduce pain and disability are yielding a panoply of available treatments ranging from nutriceuticals to chondrocyte ...
Osteoarthritis (OA) is a progressive disorder with high incidence in the ageing human population that still has no treatment currently. This disorder induces the breakdown of articular cartilage, leading to the exposure and damage of bone surfaces. For a global understanding of OA development, the ...
Intraarticular Treatments for Osteoarthritis: New Perspectives To date, no targeted treatments for osteoarthritis have been developed. Therefore the challenge for the next years is to find a treatment that may slow dow... X Chevalier - 《Current Drug Targets》 被引量: 68发表: 2010年 Genicular ...
It has been shown that GF mice and antibiotic-treated mice serve as effective experimental models for demonstrating the regulation of bone metabolism by the GM. However, they are not considered suitable as screening models for identifying probiotics as potential treatments for OP. The use of GF an...
It has been shown that GF mice and antibiotic-treated mice serve as effective experimental models for demonstrating the regulation of bone metabolism by the GM. However, they are not considered suitable as screening models for identifying probiotics as potential treatments for OP. The use of GF an...
osteoarthritis. Intriguingly, it does this by a different mechanism than any other known anti-inflammatory painkiller, through affecting the last step of making a messenger RNA, polyadenylation. This means that medicines derived from cordycepin may help patients for whom other treatments have failed. ...
to intervene with the disease process that leads to osteoarthritis, such as by blocking the pathway that represses Klotho, even in the face of a stiff extracellular matrix environment. They hope their findings can be used to develop treatments for osteoarthritis and other conditions caused by aging...